Evidence map›Paper›PMID 38672690›Full record

ArticleCancers2024

Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with

Friedemann Schad, Anja Thronicke, Ralf-Dieter Hofheinz, Harald Matthes, Christian Grah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Immediate Postoperative AbnobaVISCUMYonsei medical journal · 2025
    Article
  2. Mistletoe in Cancer Cell Biology: Recent Advances.Current issues in molecular biology · 2025
    Review
  3. Combined Immune Checkpoint Blockade and HelixorInternational journal of molecular sciences · 2025
    Article
  4. Immune Checkpoint Blockade Combined with AbnobaViscumPharmaceuticals (Basel, Switzerland) · 2024
    Article
  5. Efficacy and Safety ofIntegrative cancer therapies
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Friedemann SchadResearch Institute Havelhöhe, Network Oncology Registry, Kladower Damm 221, 14089 Berlin, Germany.ORCID 0000-0002-6928-6209
Anja ThronickeResearch Institute Havelhöhe, Network Oncology Registry, Kladower Damm 221, 14089 Berlin, Germany.ORCID 0000-0002-6421-8290
Ralf-Dieter HofheinzMannheim University Hospital, Mannheim Cancer Center, Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany.ORCID 0000-0001-5972-8504
Harald MatthesCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Hindenburgdamm 30, 12203 Berlin, Germany.ORCID 0000-0002-4053-4379
Christian GrahHospital Gemeinschaftskrankenhaus Havelhöhe, Lung Cancer Center, Kladower Damm 221, 14089 Berlin, Germany.
Forschungsinstitut Havelhöhe · DEGemeinschaftskrankenhaus Havelhöhe · DEHeidelberg University · DEHumboldt-Universität zu Berlin · DE

Funding

Abnoba (Germany) n.a.Helixor Heilmittel (Germany) n.a.
6 · The paper itself

Abstract

Immunotherapy with PD-1/PD-L1 inhibitors has significantly improved the survival rates of patients with metastatic non-small-cell lung cancer (NSCLC). Results of a real-world data study investigating add-on VA (

Indexed as

lung cancernon-small-cell lung cancerPD-1 inhibitorPD-L1 inhibitorreal-world data studysurvivalViscum album L. extracts

Identifiers

PMID38672690
PMCPMC11049173
OpenAlexW4394998778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.